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Abstract

Cancer is the second most common cause of death in the US. The most
frequently observed cancer type in women is breast cancer. A special type of breast
cancer is triple negative (TNBC) cancer that is characterized by lacking three
receptors: estrogen, progesterone and human epithelial growth factor (HER 2). The
HS578t breast cell line is a model of TNBC that also has a mutation of the p53
protein.
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Ionizing radiation is used widely in the clinic to debulk tumors before surgery
as well as post-surgery to eliminate residual tumor cells outside the surgical field.
Previous studies from our laboratory showed that inhibition of autophagy does
sensitize p53 wild type MCF-7 and ZR-75 breast tumor cells to radiation. However,
this is not necessarily the response in all breast cell lines. The Hs578t cells did not
appear to be sensitized to radiation after inhibition of autophagy using chloroquine
as a pharmacological inhibitor.
The present study was designed to build upon these previous findings and
further confirm that the Hs578t breast cell line could not be sensitized to radiation
through autophagy inhibition. Time course studies showed a reduction of viable cell
number upon irradiation of Hs578t breast tumor cells and that both autophagy and
senescence were induced. Acridine orange staining was used to examine the
acidic vacuole formation while β-galactosidase staining indicated the promotion of
senescence. Flow cytometry was used to quantify both autophagy and senescence.
Inhibition of autophagy using pharmacological inhibitors such as ammonium
chloride, or genetic silencing of autophagy by beclin1, which is a protein initiator of
autophagy, did not sensitize Hs578t breast tumor cells to irradiation. It shows from
these studies that autophagy is not necessarily cytoprotective in all breast cancer
cell lines, which should be considered in current clinical trials designed to sensitize
tumor cells to chemotherapy and radiation through inhibition of autophagy.
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Section 1
Introduction
1.1 Cancer:
The body is comprised of billions of living cells that have the capability to grow,
multiply and die in an organized manner. [1] Cancer is defined as cells growing
abnormally and out of control. Cancer can be benign when it only spreads locally
and does not invade other tissue, or it can be malignant if it metastasizes.
Because there are many different types of cancer, treatments strategies will also
differ. In general, cancer should be treated immediately upon diagnosis as
otherwise it will lead to death.
In 2013, about 1,660,290 new cases of cancer were expected to be
diagnosed and about 580,350 Americans were expected to die of cancer. [1] This
leads to cancer being the second most common cause of death in the US.
There is no single cause of cancer; there are many genetic and environmental
factors that might interact to cause cancer. Some types of cancer have been
associated with environmental factors such as smoking, exposure to ultraviolet
radiation and high-fat food. [3] Also viruses such as HPV (Human Papilloma Virus)
have been associated with cervical and head and neck cancer. [4] Mutations in
oncogenes, tumor suppressor genes and mis-match repair are thought to play
central roles in the development of cancer. [5]
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Telomerase, the specific DNA polymerase that inserts telomere repeat
segments to the terminations of telomeric DNA, is lacking in normal cells but
highly expressed in human cancer cells. [5] The expression of telomerase activity is
associated with the immortalization of cancer cells and resistance to the
development of senescence.
1.2 Breast Cancer
There are a number of different forms of breast cancer. When cancer
originates in the ducts, it is known as ductal carcinoma and if it originates in
lobules it is called lobular carcinoma. Inflammatory Breast Cancer is another type
of the breast cancer that affects primarily the skin of breast.

[2]

In general breast

cancer accounts for 22.9% of all cancers that affect women and it is more than
100 times more common in women than in men. Survival rates for breast cancer
differ greatly based on the cancer type, stage, treatment, and health status of the
patient.
The first symptom of breast cancer is typically the feeling of a lump that
differs from the rest of the breast tissue. Earliest cancers can be detected by a
mammogram. [2] Breast cancer can be a hereditary disease since in the United
States, 10 to 20 percent of patients with breast cancer have a first- or seconddegree relative with this disease. [6]
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Breast cancers can be classified by several categories. Each has its influence
on the prognosis and can affect treatment response.

[7] Breast

cancer can be

classified according to histopathology in which most cancers are derived from
epithelial cells. Alternatively, it can be classified according to the stage, where
stage 1 represents cancer that is confined to the breast and stage 4 representing
breast cancer that has metastasized to the lymph nodes and distant organs.
Another classification of breast cancer is according to the receptor status, as it
may or may not have three important receptors: estrogen receptor (ER),
progesterone receptor (PR), and HER2. The presence of the estrogen receptor
allows cancer cells to be treated with hormonal therapies such as Tamoxifen and
to have a better prognosis. [2] Another type of breast tumor, one that does not
express estrogen receptor (ER), progesterone receptor (PR), or HER2, is termed
called Triple Negative Breast Cancer. [8]

1.3 Triple Negative Breast Cancer (TNBC)
As indicated above, TNBC is a type of breast cancer that does not express
the estrogen receptor (ER), progesterone receptor (PR) or human epidermal
growth factor receptor-2 Her2/neu. [9] Triple negative breast cancers are
considered to be high aggressive with a poor prognosis. It accounts for
approximately 15%-25% of all breast cancer cases and tends to affect younger
women, African American and Hispanic women.
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Great efforts have been devoted to identify novel therapeutic targets for
TNBC; however, the heterogeneity and complexity of the biology of TNBC pose
significant challenges to development of targeted agents. Agents that have being
examined in clinical trials include the monoclonal antibody that targets the EGFR
such as cetuximab, multityrosine kinase inhibitors and poly (ADP-ribose)
polymerase (PARP) inhibitors. [10] Also anti-angiogenic therapies such as
bevacizumab are used as adjuvant therapy for women with triple-negative breast
cancer. [11]

1.4 Current Medical Treatment.

Treatment of breast cancer can include surgical intervention, radiation, and
chemotherapy. [2] Treatment can be alone or in combination and will depend on
many factors such as the type and stage of the cancer, whether the cancer is
sensitive to certain hormones, and whether the cancer overexpresses some of the
receptors such as HER2/neu. Amplification of HER2 plays a critical role in the
development and progression of certain aggressive types of breast cancer. [12]

Surgery: Surgery is used to remove the primary tumor, whether or not it has
metastasized. It is also used to test for cancer spread by checking lymph nodes
under the arm for disease inflitration. Mastectomy removes the entire affected
breast while lumpectomy removes only the breast lump and a surrounding margin
of normal tissue.[2]
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Chemotherapy: Chemotherapy refers to the use of medication to destroy or slow
the growth of rapidly multiplying cancerous cells. [2] It is considered a systemic
form of breast cancer treatment because drugs are given intravenously or orally
and enter the bloodstream to travel to all areas of the body’s in order to reach
cancer cells. There are three major types of chemotherapy: neo-adjuvant which is
used before surgery to shrink the tumor size, adjuvant which is given after surgery
to reduce risk of recurrence, and palliative which is given when the cancer
spreads beyond the breast and localized lymph nodes and is used to control but
not to cure the cancer. Chemotherapy is given in cycles of treatment, followed by
a recovery period. The total chemotherapy treatment usually takes several
months to one year, depending on the type of drugs given.

[2]

According to the breast cancer types and the patient condition, physicians
usually try to personalize the breast cancer treatments. Drugs that are frequently
used for adjuvant chemotherapy in breast cancer are cyclophosphamide, 5fluorouracil, and taxol. [7]
Despite the improvement in the diagnostic tests that are used in early
detection and understanding of basic molecular biology of breast cancer, around
30% of all patients with early-stage breast cancer have recurrent disease.
Reduction in the effectiveness of chemotherapy is often due to development of
resistance. [7] There are several mechanisms of drug resistance in breast cancer.
For instance, resistance to Tamoxifen, which is an estrogen antagonist that binds
to the estrogen receptor (ER) and inactivates it, has been developed by cancer
cells by reducing estrogen receptor expression.[46]
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Hormonal Therapy: Hormonal therapy is another form of systemic therapy that
is used as adjuvant therapy to reduce the risk of cancer recurrence.

[2]

Estrogen

stimulates the growth of cancers that are positive for the hormone receptor.
Generally about two-thirds of breast tumors are hormone receptor-positive and
express the receptors for the hormones estrogen and/or progesterone.The
mechanism of action of hormonal therapy involves interfering with estrogen
acting on breast cancer cells or lowering estrogen levels. Hormonal therapy is not
effective for patients whose tumors are hormone receptor negative such as triple
negative tumors. [2]
There are many drugs that are used as hormonal therapies. Selective
estrogen receptor modulator or SERMs have estrogen-like agonist properties in
some tissues but work as anti-estrogens in other tissues.[7] Tamoxifen is an
estrogen antagonist that is an example of a SERM that can be given after surgery
for 5 years to reduce the chances of recurrence of the cancer by about half,
thereby significantly prolonging patient survival. Tamoxifen also reduces the risk
of a new breast cancer in the other breast. [13]
Aromatase Inhibitors (AIs) represent another form of hormonal therapy that
interferes with estrogen production in the breast tissue of post-menopausal
women and which are used to treat both early and advanced breast cancer.

[14]

Because of their effectiveness, AIs are the most clinically used antihormonal
treatment for breast cancer in postmenopausal women. However, AIs are
ineffective in pre-menopausal patients where high levels of estrogens are being
produced in the ovaries. [14]
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Targeted therapy for breast cancer
Changes in the activity of specific genes have been associated with breast
cancer development, and researchers have been able to discover newer drugs
that specifically target these changes. The mechanisms of action of these
targeted medications differ from that of standard chemotherapy drugs, and they
often have less severe side effects. [15] About 1 in 5 patients with breast cancer
has high levels of a growth-promoting protein known as HER2/neu on their
surface. These breast cancers have a greater ability to grow and spread more
aggressively and a number of drugs have been developed that target this
protein. [2]
Trastuzumab is a monoclonal antibody that binds to HER2 and can help slow
the growth of cancer cells that overexpress HER2. It may also stimulate the
immune system to more effectively attack the cancer. [16] Trastuzumab is often
used as adjuvant therapy for HER2-positive cancers with chemotherapy to
reduce the risk of cancer recurrence. In the later course of treatment,
trastuzumab can be give alone, usually for a total of a year of treatment.

[2]

Bevacizumab (also known as Avastin) is another monoclonal antibody that can
be used in patients with metastatic breast cancer. This antibody antagonizes the
vascular endothelial growth factor, which is a protein that helps tumors to form
new blood vessels. Bevacizumab is given by intravenous (IV) infusion. It is
commonly used in combination with chemotherapy.
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[17]

Bevacizumab was first accepted by the US Food and Drug Administration
(FDA) as part of the treatment for metastatic breast cancer in 2008, but is no
longer approved for this purpose.[18]
Another example of targeted therapy is Everolimus, which blocks mTOR ( the
mammalian target of Rapamycin) which is a protein in cells that normally
promotes growth and division. [15] By blocking mTOR, Everolimus can prevent
cancer cells from growing. Everolimus may also prevent tumors from forming new
blood vessels. It is approved to treat advanced tumor cells and earlier stage
breast cancer, with other hormone therapy drugs, and in combination with other
treatments. Bevacizumab is not effective in patients with triple-negative breast
cancer (TNBC) because of the lack of targeted therapy for these patients.

[15]

Radiation therapy:
Radiation therapy involves the medical use of ionizing radiation to control or kill
cells in cancer treatment. [20] If the cancer is localized in one part of the body, then
radiation therapy may be curative, or as adjuvant therapy to prevent tumor
recurrence after surgery or with chemotherapy. The treatment goal of radiation
therapy depends on the tumor type, location, and stage, as well as the general
health of the patient. Ionizing radiation produces its effect by damaging the DNA
of exposed tissue leading to cellular death. In photon therapy, the radiation
produces double strand breaks which is more effective in promoting cancer death
than single strand breaks. [20]
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In the Law of Bergonie and Trebondeau, radiation is more damaging for
rapidly dividing cells such as epithelial cells of the gastrointestinal tract than nondividing cells and neurons. [21] During IR exposure, both single-stranded DNA
breaks (SSB) and double-stranded DNA breaks (DSB) occur. DSB have more
lethal effects than SSB.[21]
The measure of radiation is in terms of Rads of Grays (Gy) where 100 rads is
equivalent to 1 Gy. The radiation dose that will be administered depends on many
factors including the stage and size of the tumor, as well as the patient’s health.
[20]

In the clinic, the total doses for radiation of tumors range from 40 to 80 Gray,
and usually these doses are given in the form of fractionated doses of 1.8 – 2 Gy
over a period of time. [20] The rationale for using fractionated doses is to allow the
healthy cells to recover since tumor cells are less effective in repairing damage to
their DNA. [21] Also fractionated radiation will allow the specific cycle resistant
tumor to enter to another cycle where they might be more radio-sensitive. With
fractionated doses of radiation, hypoxic and more radio-resistant cells might reoxygenate between fractions.
Radiation therapy is generally not of itself painful to the patient. However, the
severity and longevity of side effects will depend on the organs involved in
receiving the radiation, the co-administration of chemotherapy, and the patient’s
health.[20] The most common side effects of radiation are nausea, vomiting,
gastrointestinal ulcers, edema, abdominal discomfort, and infertility in rare cases.
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1.5 Cellular response in Cancer:
Apoptosis, autophagy, necrosis, and senescence are cellular responses to
external stresses such as radiation and chemotherapy.[22] Cellular responses may
equilibrate cell death with survival of cells. This balance plays a critical role in the
ultimate decision of cancer cell fate.

Apoptosis
Apoptosis, or type I programmed cell death, was first described by Kerr et al in
1972. Apoptosis is characterized by specific morphological and metabolic
changes of dying cells, which includes membrane shrinkage, nuclear
fragmentation, and loss of adhesion to extracellular matrix.

[23] Chromosomal

DNA

cleavage and externalization of phosphatidylserine, Annexin I and calreticulin are
among specific biochemical abnormalities of apoptosis. In response to stress,
cells are producing intracellular responses that initiate apoptosis and lead to cell
death.

One of the most important regulators of apoptosis is the caspase family, which
are endoproteases that hydrolyze peptide bonds and lead to activation of
signaling pathways and ultimately apoptosis. [23] Caspases that are involved in
apoptosis have been subdivided according to their mechanism of action to either
initiator caspases (caspase-8 and -9) or executioner caspases (caspase-3, -6,
and -7).
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There are two basic pathways that regulate apoptosis, the intrinsic or
mitochondrial pathway and the extrinsic or receptor-mediated pathway. [22] In the
extrinsic pathway, Fas, which is plasma membrane death receptor, binds with its
extracellular ligand Fas-L. Formation of Fas/Fas-L complex initiates cell death and
recruits death domain-containing protein (FADD) and caspase 8 to form the
death-inducing signaling complex (DISC). DISC activates pro-caspase-8 and procaspase-3.
In the intrinsic pathway, activation of apoptosis is regulated by mitochondrial
pro-enzymes. [22] When the cell is stimulated by external or internal stimuli, outer
mitochondrial membranes become permeable and cytochrome c is then released
into the cytosol. The release of cytochrome leads to recruitment of pro-caspase-9
and apaf-1 to form the apoptosome which downstream activates the caspase 9/3
signaling cascade of apoptosis.
In many types of cancer cells, the Bcl 2 family proteins are overexpressed.
Bcl2 is one of the major regulators of apoptosis.[22] Reduction of Bcl-2 expression
is permissive for apoptotic responses to anticancer drugs, while overexpression
of Bcl-2 leads to resistance to chemotherapeutic drugs and radiation therapy. The
Bcl-2 family consists of of pro-apoptotic members such as Bax, Bak, Bad, Bcl-XS,
Bid, Bik, Bim and Hrk, plus further anti-apoptotic members such as Bcl-2, Bcl-XL,
Bcl-W, Bfl-1 and Mcl-1.
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Another important proapoptotic factor and tumor inhibitor is p53, which acts
as a tumor suppressor preventing cancer. Since p53 activates apoptotic cell
death by promoting a number of positive regulators of apoptosis, the antitumor
effects of many chemotherapeutic agents may be mediated by targeting p53related signaling pathways. [24]
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Ouyang L et al (2012)
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Autophagy

The process of autophagy was first revealed by Keith R. Porter and his
postdoctoral student Thomas Ashford. [28] It involves the catabolism of
unnecessary or dysfunctional cellular components, and is initiated by the
formation of autophagosomes, double membrane-bound structures surrounding
cytoplasmic macromolecules and organelles, designated for recycling.

[26]

Autophagy can promote cellular survival during starvation by maintaining cellular
energy levels. [28] It plays a crucial role in a homeostasis by controlling
physiological processes including cell differentiation, cell survival and death.

[22]

The autophagy process consists of different steps, including induction step,
cargo recognition and selection, vesicle creation, autophagsome-vacuole union,
and analysis of the cargo followed by release of the degradation yields back into
the cytosol. [22] Different ATG (Autophagy related genes) are essential in these
steps. In the induction step, starvation or rapamycin treatment leads to activation
of the Unc-51-like kinase 1 (ULK1) and -2 (ULK2), also FIP200 (the focal
adhesion kinase family-interacting protein of 200 kD). FIP200 forms a complex
with ULKs and mammalian Atg13 and identifies to the phagophore.
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In the cargo recognition step, p62/sequestosome 1 (SQSTM1) binds both
poly- or mono-ubiquitin through its ubiquitin-associated (UBA) domain and the
mammalian Atg8 homolog, LC3 (microtubule-associated protein 1 light chain 3).
[27]

In the formation of autophagosome step, multiple Atg proteins are recruited to

the phagophore to take part in autophagosome formation. After completion of
autophagosome formation, Atg8 attached to the outer membrane is cleaved from
PE (phosphatidylethanolamine) by Atg4 leadsing to autophagsome-vacuole
fusion.

The complete process of autophagy is called Autophagic flux. To confirm the
autophagic flux, p62 may be used as a marker.

[27]

p62 accumulates when

autophagy is inhibited, and degraded levels of p62 can be observed when
autophagy is induced
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One of the crucial regulators of autophagy is p53, which is the tumor
suppressor gene most commonly mutated in human cancers. p53 has a dual
effect on autophagy. [25] One way for p53 to induce autophagy is through activation
of AMPK kinase, which leads to activation of TSC1 and TSC2 kinases, and to the
acute inhibition of mTOR kinase (mammalian target of rapamycin). Kroemer et al
reported that cytoplasmic but not nuclear p53 has the autophagy-inhibiting
function. [47]
Autophagy has many different roles in cancer. [29] In the literature, it has been
shown that chemotherapeutic drugs and radiation can lead to a cytoprotective
form of autophagy in tumor cells, in which the sensitivity of tumor to radiation or
chemotherapy is increased upon inhibition of autophagy. This increased in
sensitivity after blockage of autophagy occurs by promoting apoptosis.
Cytoprotective autophagy has its clinical implication, in that theoretically a patient
can take an autophagy inhibitor such as chloroquine that leads to sensitization of
tumor cells to radiation or chemotherapy.
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Another (lack of) function of autophagy is to be non-cytoprotective, in which
inhibition of autophagy does not sensitize tumor cells to radiation or
chemotherapy. [29] Cytotoxic effect is the third role of autophagy in cancer that
leads to either killing of cells of itself or acts as a precursor to apoptosis. The main
basic difference between cytotoxic and cytoprotective autophagy is that upon
inhibition of autophagy in cytoprotective autophagy, the cells are sensitized to the
treatment, while when cytotoxic autophagy is inhibited, the cells become less
sensitive to the treatment.

The fourth function of autophagy in cancer is Cytostatic Autophagy.

[29]

In our

laboratory, it has been shown that the combination therapy of vitamin D and
radiation leads to a more pronounced growth inhibition of non–small cell lung
cancer cells than for radiation alone. Also pharmacologic inhibition of autophagy
protects the cells from the sensitization to radiation by vitamin D. The relationship
of cytostatic autophagy with senescence is currently under investigation in our
laboratory.
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1.5.3 Senescence
Cellular senescence refers to the irreversible arrest of cell proliferation that
occurs when cells experience oncogenic-induced stress or other forms of stress
such as radiation and chemotherapy. [30] Since there is no known physiological
inducer that has the ability to stimulate senescent cells to reenter the cell cycle,
the senescence is considered irreversible. [32] One of the reasons why normal cells
do not proliferate indefinitely is dysfunction of telomeres. Telomeres cap the ends
of linear chromosomes and protect them from degradation or fusion by DNArepair processes. In some cases, telomeres become short and dysfunctional
which trigger a classical DNA damage response (DDR). DNA damage and
dysfunctional telomeres induce p16, which acts as a tumor suppressor that is
implicated in the prevention of cancers and offers a second obstacle to prevent
the growth of cells.

Maintenance of the senescence growth arrested state is controlled
mainly by either or both of the p53/p21 and p16INK4a/pRB tumor suppressive
pathways. [31] Both pathways have multiple upstream and downstream regulators.
p53 and pRB are transcriptional regulators. p21 is a downstream effector of p53,
while p16INK4a is a positive upstream regulator of pRB effectors. p21 and pRB
are cyclin-dependent kinase inhibitors and strong negative regulators of cell cycle
progression.
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Campisi J et al (2007).
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1.5.4 Necrosis
Necrosis is a result of cell injury that leads to the premature death of cells by
autolysis. Infection, toxins, or trauma are external factors that lead to necrosis. [33]
During necrosis, cells initial swell then the plasma membrane breakdowns, and
cells are rapidly lysed. Necrosis can be tested in vitro by measuring permeability
of the cell plasma membrane to vital dyes like trypan blue, and efflux of cytosolic
enzymes such as lactate dehydrogenase, or creatine kinase.

Binding of death ligands such as TNFa, TNF-related apoptosis-inducing
ligand (TRAIL) and Fas ligand (FasL) to their receptors leads to assembly of
caspase-8 and receptor-interacting serine threnoine kinase RIP1and RIP3. The
RIP family plays a critical role in necrosis and leads to stimulation of metabolic
enzymes like glycogen phosphorylase (PYGL), glutamate-ammonia ligase (GLUL)
and glutamate dehydrogenase 1 (GLUD1). [34] Enhancement of metabolic
enzymes is accompanied by production of reactive oxygen species (ROS) which
is dependent on the NADPH oxidase to forms complexes with the adaptor
molecules such as Tumor necrosis factor receptor type 1-associated DEATH
domain protein (TRADD).
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Ouyang L et al (2012)
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1.5.5 Mitotic catastrophe
The term mitotic catastrophe is defined as incorrect entrance of cells into
mitosis which can be caused by chemical or physical stresses.

[35]

Agents that

affect the stability of microtubules, anti-cancer agents, and ionizing radiation are
considered to trigger mitotic catastrophe. Cells that undergo mitotic catastrophe
are characterised by abnormalities of chromosome segregation.

Mitotic catastrophe is characterized by elevation of cyclin B1 which is a
regulatory protein involved in mitosis, activation of p53 which is a tumor
suppressor protein, persistent activation of SAC (Spindle- assembly checkpoint)
which inhibits anaphase causing chromosome missegregation, and caspase-2
activation. [35]

1.6 Previous studies
In our laboratory, it has been shown that irradiation of p53 wild type, and
estrogen receptor-positive MCF-7 and ZR-75-1 breast tumor cells induce
autophagy. The autophagy produced by radiation alone was found to be
cytoprotective in that both pharmacological and genetic inhibition of autophagy
increased sensitivity to radiation. The combination therapies of vitamin D3 and
radiation promote cytotoxic autophagy that upon inhibition the radio-sensitization
by vitamin D is markedly attenuated. [36] [38]
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It has been shown in much of the current literature that the cellular
response to radiation in many cell lines is that of autophagy.

[37]

It has been

shown in our laboratory that the inhibition of autophagy does sensitize MCF-7
and ZR-75 breast tumor cells to radiation. [36] However, this is not necessarily the
response in all breast cell lines. In the 4T1 syngeneic murine breast tumor cells
could not be sensitized to radiation in vitro by using pharmacological inhibitor of
autophagy with chloroquine treatment, by silencing of the autophagy- related
gene Atg12, or by chloroquine in vivo. [49] Also in Hs578t cells, which are a
mutant p53 triple negative cell line, pharmacological autophagy inhibition did not
increase radiation sensitivity.

Upon irradiation, Hs578t cells undergo autophagy; however, the combination
of radiation with the autophagy inhibitor, chloroquine, does not sensitize this cell
lines to radiation. Also, Hs578t cells show minimal apoptosis upon radiation alone
and furthermore apoptosis does not increase with autophagy inhibition.
(Chakradeo S under revision)
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1.7 Hypothesis
Since previous data using pharmacological inhibition of autophagy shows that
the Hs578t cell line does not become sensitized to radiation, the effect of
autophagy inhibition on radiation sensitivity using another pharmacological
inhibitor and genetic approaches were recommended to be performed.
(Chakradeo S under revision). In addition, to interfere with autophagy, beclin 1
was silenced using siRNA techniques.

Based on previous results in Hs578t, the hypothesis for this project was that
Autophagy is a general response of breast cancer cells to radiation, but that
inhibition of autophagy may not sensitize breast tumor cells to radiation (nonprotective autophagy).
Our aims were:
AIM 1: Evaluation of the response of Hs578t to radiation
A- Determination of the effect of radiation on autophagy
B-Determination of the effect of radiation on apoptosis
C-Determination of the effect of radiation on senescence
AIM 2: Inhibition of autophagy genetically and pharmacologically
A-Assessment of the effect of autophagy inhibition on radiation sensitivity
B- Assessment of the effect of autophagy inhibition on senescence
C- Assessment of the effect of autophagy inhibition on apoptosis

35

Section 2: Materials and Methods
2.1 Material:
MEM Alpha media- L glutamate was purchased from Gibco. Trypsin-EDTA
(0.25% trypsin, 0.53 mmol EDTA-4Na) was obtained from HyColne. PBS (pH=7)
was obtaining from Gibco. X-gal (5-bromo chloro-3) was purchased from Fermenas
Life Sciences. Fetal Bovine Serum was obtained from Serum source international.
Acridine Orange was purchased from Invitrogen.
2.2 Cell lines:
Breast tumor cells Hs578t were obtained from American Type Culture collection
(ATCC). Hs578t cells were developed to silence the expression of Beclin1. The
lentiviral shRNA constructs to target Beclin-1 were kindly provided by Dr. Hisashi
Harada (Virginia Commonwealth University, VA, USA). The shRNA constructs were
transfected into 293T cells along with lentiviral packaging plasmids. The lentivirus
shed into the medium was then used to infect the breast tumor cells. The retrovirus
pBp-RNA expressing constructs were kindly provided by Dr. Wataru Nakajima
(Nippon Medical School, Kawasaki, Japan). The constructs were transfected into
293T cells along with the packaging plasmids. The retrovirus shed into the medium
was collected and used to infect Hs578t cells.
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2.3 Cell Culture and Treatment:
Hs578t cells were grown from frozen stocks in MEM-alpha supplemented with
20% FBS, and penicillin/ streptomycin (0.5ml) in 100 ml medium. All cells were
maintained at 37°C under a humidified 5% CO2 atmosphere. Cells were kept in T75
flasks (Cellstar), sub-cultured and trypsinized with (0.25% trypsin, 0.03% EDTA) for
4- 6 minutes upon reaching confluence and then deactivated with complete MEM
alpha media. Prior to any experiments, cells were examined by microscope for any
fungal and bacterial infections.

2.4 Cell Viability:
Trypan blue exclusion dye was used to identify viable cells. Cells were plated in
triplicate at a density of 6,000 to 10,000 cells per well and allow to adhere
overnight. The following day, cells were treated with ammonium chloride, CQ, or 3MA for 3 hours and then followed by a radiation dose 5x2 Gy. After radiation, media
was changed and then cells were counted at various time points. Trypsin (0.25%
Trypsin-EDTA) was added to cells and was incubated for 5-7 min at 36 C0. Then
cells were stained with Trypan Blue (0.4% Trypan Blue). Haemacytometer with
phase contrast microscopy was used to count cells on Days 1, 3, 5, and 7 postradiation.
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2.5 MTT Assay To determine the effective dose of Ammonium Chloride
The MTT assay was used to determine the effective dose of ammonium chloride
for further experiments. Cells were plated in 96 well plates at a density of 5,000
cells/well in 200µL of MEM alpha Medium. Cells were allowed to adhere to the
plates overnight and then treated with different doses of ammonium chloride. The
doses of ammonium Chloride ranged from 1mM-10mM. Cells were incubated with
drug for 72 hours. Then media was aspirated and cells were incubated for 3 hours
with the MTT solution (2mg/ml PBS) at 37 C0. After removal of the MTT solution,
autoclaved DMSO was added and plates were shaken for 10 min.

In MTT assay, MTT dye ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) becomes reduced to an insoluble formazan inside living cells. DMSO was
used as solubilizing agent to dissolve insoluble purple formazan product into a
colored solution. Then Absorbance was read at 490 nm using (KC Junior software,
EL800 Universal Microplate Reader).

2.6 Clonogenic Survival Assay:
To evaluate the ability of a single cell to form a colony, clonogenic assay was
used. In triplicate plates, cells were plated at a density of 150 cells per well. After 14
days, cells were fixed with 100% methanol, air-dried and stained with 0.1% v/v
crystal violet (Sigma 3886)
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2.7 Evaluation of Autophagy by Acridine Orange Staining
10,000 cells were plated in 6-wells plates and allowed to adhere for 24 hours
prior to being treated and irradiated. At various time points at day 1, 3, 5, and 7
post-radiation, media was removed and cells were washed twice with PBS. Acridine
orange dye was prepared in the dark at a dilution of 1 to 10,000 of media and
incubated with cells for 15 minutes. Cells then were washed with PBS. Fluorescent
micrograph images were taken using an inverted fluorescence microscope
(Olympus). Increased numbers of acidic vesicular organelles were used as an
indication of autophagy.
2.8 Evaluation of Senescence by Beta Galactosidase Staining Assay
The state in which cells stop growing but stay metabolically active is called
senescence or biological aging. -Galactosidase staining is used to detect the
senescence after exposure of cells to radiation. In senescence B-galactosidase
enzyme is overexpressed and cleaves the substrate X-Gal. Cells were plated and
allowed to adhere overnight then were treated and radiated with dose 5x2 Gy. At
different time points on Day 1, 3, 5, and 7 post radiation, cells were washed twice
with 1XPBS and fixed with fixing buffer that consists of 0.2 glutaraldehyde/2%
formaldehyde for 10 minutes followed by aspiration of the fixing solution. Cells were
washed twice by 1XPBS followed by adding staining buffer which consists of 1
mg/mL 5-bromo-4-chloro-3-inolyl-β-galactosidase in dimethylformamide (20 mg/mL
stock), 5 mM potassium ferricyanide, 150 mM NaCl, 40 mM citric acid/sodium
phosphate, 2 mM MgCl2. Staining buffer was incubated with cells overnight in CO2
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incubator to maintain pH of solution at 6. On the next day, cells were washed with
1XPBS and images where taken using light microscope.

2.9 Western Immunoblotting
A- Protein Collection
Westren immunoblotting is used to indicate the expressions of different proteins.
To isolate proteins, cells were plated at cell density of 70,000-100,000 cells per
10mm cell culture dish. Then cells were treated with the appropriate treatment and
washed with 1XPBS at assigned time points. After washing with PBS, 100 to 500 µl
of lysis buffer (1:100 phosphatase inhibitors and 1:50 protease inhibitors suspended
in M-PER mammalian protein extraction reagent (Thermo scientific #78501) was
added for 5 minutes. The lysate was then centrifuged for 5 minutes at 10,000 rpm.
B-Determination of Protein Concentration by using Bradford method
Bradford reagent (Bio-Rad 500-0205) is used in the Bradford method to
determine the concentration of proteins. 20 µg of equal aliquots of total cell lysate
was loaded onto a polyacrylamide gel (10-12% based on the molecular weight of
proteins that being analyzed). By using SDS-PAGE running buffer and 170
milliamps constant current, proteins were separated for 1-2 hours. Then proteins
were transferred onto a PVDF membrane for 1.5 hours and washed 4 times with
PBS containing 0.01% Tween for 15 minutes in each time.
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C-Immunoblotting
The membrane was blocked with TBS-Tween buffer containing 5% dry milk for
0.5 hour. Then primary antibody was added on the membrane and left overnight in
4 C0. The following day, the primary antibody was washed out with TBS-Tween
buffer for three times each for 15 minutes. Then secondary antibody was added
and incubated with membrane for one hour at room temperature and then washed
with TBS-Tween buffer. West Femto Maximum Sensitivity substrate (Thermo
Scientific # 34095) and Premium quality X-Ray films (PHENIX) were used to
develop the membrane. The dilution of primary antibody was 1:1000 in blotto and
the dilution of secondary antibody and beta- actin antibody were 1:5000 in blotto.

2.10 Flow cytometer Analysis (FACS)
2.10.1 Quantification of acridine orange staining by flow cytometry for
autophagy
FACS analysis was used to quantify the amount of autophagic vacuoles which
are positively stained with acridine orange staining. After radiation of the cells for
three days, cells were collected and suspended with acridine orange staining
solution of 1 in 10,000 dilution in PBS for 10 minutes. In FACS analysis, for each
gated region at least 10,000 cells should be collected.
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2.10.2 Quantification of β-galactosidase staining by flow cytometry for
Senescence
Confluent plates with hs578t cells line were treated with radiation for three days
and on the day of staining cells were incubated with 100 nM of bafilomycin A1 in
fresh medium to induce lysosomal alkalinization and left incubated at 37C 0 and 5%
CO2 for 1 hour. After incubation, C12FDG working solution was added to each well
in amount to make the final concentration 33 μM and was continued incubation for
another 1 hour. Media was then aspirated and cells were washed twice with PBS.
Cells were harvested and collected for centrifugation at speed 1500 rpm and
resuspended in PBS. C12FDG is a substance that is hydrolyzed by upregulated βgalactosidase enzyme and becomes fluorescent at wavelength of 500–510 nM.
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Section 3: Results
3.1 Influence of Radiation on the growth of Hs578t breast tumor cells
As described in the Introduction, radiation is used as adjuvant therapy in breast
cancer to eradicate any remaining cancer cells post-surgery. Fractionated
radiation doses are used in the clinic, where patients receive multiple small doses
of 2 Gy. Previous studies from our laboratory have shown that radiation promotes
protective autophagy in MCF-7 and ZR-75 breast tumor cells and that
pharmacological or genetic inhibition of the autophagy induced by radiation leads
to growth suppression and cell death, primarily through apoptosis. [36] [38] In
contrast, the 4T1 syngeneic murine breast tumor cells could not be sensitized to
radiation in vitro by using pharmacological inhibitor of autophagy with chloroquine
treatment, by silencing of the autophagy- related gene Atg12, or by chloroquine in
vivo. [49]

In this study, cells were plated, irradiated over period of three days, and then
counted on Days 1, 3, 5, and 7-post radiation. In Figure 3.1, irradiated cells show
initial cell death with slight recovery from days 3 to day 5 but primarily growth
arrest. The results represent the average of three experiments with standard
errors.
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Cells Viability Assay
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No of viable cells
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Figure 3.1 Effect of radiation on viable cell numbers. Upon radiation with 5 X 2 Gy, Hs578t
cells showed growth arrest post day 5 of radiation. In each experiment, triplicates were
used. Three different experiments were done to confirm the results. (* p value< 0.05
compared IR to control using ANOVA followed by tukey)
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3.2 Effect of radiation on Hs578t breast tumor cells.
Autophagy is a homeostatic catabolic process that degrades impaired proteins
and organelles and recycles them to sustain metabolic activity. Autophagy has a
different effects in cancer, one role as tumor suppressor by preventing the
accumulation of mutant proteins and organelles, and the other role
(Cytoprotective) helping the existing tumor cells to survive by provide them with
nutrients and metabolic precursors. [40] Previous studies from our lab have shown
that in MCF-7 breast tumor cells radiation induces a cytoprotective autophagy
because interference with that autophagy leads to growth suppression and cell
death. [38]

Acridine orange staining was used to evaluate the effect of radiation on
autophagy in Hs578t breast tumor cells as it is widely used to detect the presence
of autophagic vacuoles. Acridine orange is a lysomotropic dye that becomes
trapped upon entering acidic compartments. Under low pH conditions, Acridine
orange emits orange light when excited by blue light.
In Figure 3.2, it is clear that the Hs578t breast cancer cells have minimum
basal autophagy while irradiated cells showed an increased acridine orange
staining and development of the orange colored puncta, which is indicative of the
induction of autophagy. Serum starved cells were used as positive control.
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CONT

Day 3 post radiation

IR Day3 post radiation

IR Day 7 post radiation

Serum starved positive control

Figure 3.2: Induction of autophagy in Hs578t cells after radiation. Autophagy induction was
performed using Acridine orange staining on day 1,3,5, and 7 post radiation with 5X2 Gy.
Three different experiments were done to confirm the results.
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3.3 Quantification of Autophagy upon Radiation Using Flow Cytometery
Another technique that is used to evaluate the autophagy is the quantitation
of acidic vacuoles by Flow Cytometery. In this experiment, cells were plated,
irradiated over a period of three days, and acidic vacuoles were quantified on Day
1, 3, and 5-post radiation.

In Figure 3.3, Hs578t control cells show minimum basal autophagy, while
irradiated cells show the promotion of autophagy. The same experiment was
repeated three times and in all three times statistical difference were observed
between irradiated cells and control cells. Therefore it appears that irradiation of
Hs578t breast tumor cells promotes autophagy.
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FACS analysis of Autophagy
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Figure 3.3 Quantification of radiation induced autophagy. Hs578t cells were plated and
irradiated with fractionated radiation (5×2Gy) and then were analyzed using Flow cytometry
on days 1,3, and 5 post radiation. In each experiment, triplicates were used. Three different
experiments were done to confirm the results. (* p value< 0.05 compared IR to control
using ANOVA followed by tukey). AVO= acidic vesicular organelles.
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3.4. Induction of senescence in irradiated Hs578t cells.
Cellular senescence is a phenomena in which a cells stop to divide, but stay
metabolically active. It has been reported that ionizing radiation promotes
senescence in both normal and tumor cells. [30] Our laboratory has previously
reported the induction of accelerated senescence by ionizing radiation and that
this is largely p53 dependent. [39]
The Hs578t breast cell line is mutant in the tumor suppression protein, p53.

[48]

The β galactosidase-staining assay is used to distinguish proliferating and
senescent cells. In senescent cells, beta galactosidase enzyme is overexpressed
and upon adding x-gal which is a chromogenic substrate to the cells, - β
galactosidase enzyme cleaves the x-gal and gives insoluble blue substance at pH
6.
In Figure 3.3, there is -gal staining upon radiation of Hs578t breast cells,
which suggests that induction of senescence upon radiation is not dependent on
functional 53 at least in Hs578t cells.
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CONTROL
Day 5 post-radiation

IR (5X2 Gy)
Day 5 post-radiation

Figure 3.4: Staining of the cells using X-gal shows induction of senescence upon
irradiation of Hs578t breast cell line. Three different experiments were done to confirm
the results.
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3.5 Quantification of Senescence upon Radiation Using Flow Cytometery

The flow cytometry method is extremely useful in quantitative analysis of
cellular senescence phenomenon. This flow cytometric analysis is able to detect
the hydrolysis of 5-dodecanoylaminofluorescein di-β-D-galactopyranoside
(C12FDG), a membrane-permeable and nonfluorescent substrate of βgalactosidase, which, upon cleavage, stays inside the cytosol and produces green
fluorescence. Flow Cytometery allows estimation of the enzyme activity and also
provides quantitative information on the population size of SA β-Gal-positive
cells.[51]

In figure 3.5, irradiated cells show promotion of senescence as compared to
control. Same experiment was repeated three times and in all three times
significant differences were observed between irradiated cells and control cells.
Therefore it appears that irradiation of Hs578t breast tumor cells promotes
senescence.
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FACS Analysis of Senescence After Radiation
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Figure 3.5 Quantification of radiation induced senescence .Hs578t cells were plated and irradiated
with fractionated radiation (5×2Gy) and then were analyzed using Flow cytometry on days 1, 3, 5
and 7 post- radiation. In each experiment, triplicate samples were used. Three different

experiments were done to confirm the results. (* p value< 0.05 compared IR to control on
Day 7 using ANOVA followed by tukey)
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3.6 Pharmacologic and Genetic Inhibition of Autophagy
3.6.1 Determination of the effective dose of Ammonium Chloride

It has been shown that autophagy might lead to cancer cell resistance to
chemotherapy and radiation treatment. Inhibition of autophagy can lead to the
sensitization of resistant cancer cells to anticancer treatment. [40]
Inhibition of autophagy can be performed genetically and pharmacologically.
There are many different chemical agents that can inhibit autophagy such as
chloroquine which is used clinically, 3 methyl adenine, bafilomycin and ammonium
chloride. Also silencing of autophagy related proteins such as Atg5, Atg7 and
beclin1 leads to inhibition of autophagy.
In our experiments, ammonium chloride has been used as an example of a
pharmacological autophagic inhibitor. Ammonium chloride is an organic
compound that is capable of inhibition of the fusion of autophagosome with the
lysosome in the last step of degradation of the autophagosome contents. [41] In
order to use ammonium chloride in the experiments, non-toxic doses were first
determined using the MTT assay. Based on the previous literature, studies have
shown that 10 mM is an effective dose that inhibits autophagy.

[41]

In figure 3.6,

the 10 mM ammonium chloride showed no significant differences between control
and NH4Cl treated cells.
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MTT assay for NH4CL
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10 mM

NH4Cl concentrations in mM

Figure 3.6. Determination of effective dose of ammonium chloride using the MTT
assay. The dose of 10 mM ammonium chloride has relatively low toxicity profile. The
experiment was repeated twice and the results given are the average of two
experiments with standard Errors. No statistical differences were detected between
control cells and cells treated with 10 mM NH4CL.
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3.6.2 Effect of the autophagy inhibitor, ammonium chloride (NH4CL), on
colony formation

Clonogenic survival assays study the ability of a single cell to form a colony.
Cells were plated in triplicate in six wells tissue culture dishes at a density of 150
cells per well and allowed to grow for 10-14 days.

The clonogenic survival assay in Figure 3.7 indicates lack of sensitization of
Hs578t cells to radiation even after inhibition of autophagy. Two conditions, IR
(5*2 Gy) and IR + NH4CL were compared to asses statistical significance. The
experiment was repeated three times and in all three times, no statistical
difference was observed between irradiated cells and cells treated with IR and
NH4Cl (10 mM) in their colony forming abilities. It can be said here that Hs578t
cells treated with IR when also treated with NH4Cl do not become sensitized
which is in accordance with our previous data. Therefore it appears that Hs578t
breast tumor cells may not be using autophagy as a mechanism to survive. Hence
it can be said that the role of autophagy here is a non-cytoprotective role.
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Clonogenic Survival Assay for NH4CL
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Figure 3.7 Clonogenic survival assay. Ammonium Chloride (10 mM) does not sensitize

Hs578t breast tumor cells cells to radiation. In each experiment, triplicate samples were
used. Three different experiments were done to confirm the results. (* p value< 0.05 IR
compared to control using ANOVA followed by tukey) (No statistical differences is
observed between IR treated cells alone or combination of IR and NH4CL )
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3.6.3 Ammonium Chloride was effective in inhibition of autophagy based on
Acridine orange staining
The findings in the previous figure are not consistent with much of the literature
relating to autophagy. It was therefore necessary to confirm that the treatment
indicated actually was effective in inhibiting autophagy in the Hs578t cells.
Staining of vacuoles with orange is an indication of induction of autophagy while
yellowish color shows inhibition of autophagy since ammonium chloride interferes
with the acidity of the lysosomes.

In Figure 3.8, control cells show a low basal level of autophagy, while
irradiated cells undergo induction of autophagy. In cells treated with ammonium
chloride, it is clear that autophagy has been inhibited as indicated by the yellowish
color. Inhibition of autophagy by NH4CL occurs in the last step, this explains why
there are many vacuoles that stained with the yellowish color.
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Day 1 post-Radiation
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IR 5 X 2 GY Day 3 post-Radiation
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Day 3 post-Radiation
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Figure 3.8 Determination of the inhibition of autophagy by 10mM Ammonium chloride using Acridine
orange staining. Three different experiments were done to confirm the results. All images have

the same magnification 20X.
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3.6.4 Silencing of Beclin1
One classical strategy for interfering with autophagy is by silencing of
autophagy related genes. Consequently, we developed an Hs578t breast cell line
(Hs578t/Beclin-) in which Beclin was silenced. Beclin-1 and its binding partner
class III phosphoinositide 3-kinase (PI3K), are essential for the initiation and
formation of the autophagosome in autophagy. [22]

In Figure 3.9 , western blotting indicates a significant decrease in the levels
of Beclin1 as compared to control.

60

Beclin -/- Control

Beclin 1

ß actin

Figure 3.9 Western Immunobloting to determine silencing level of Beclin1.
Experiment was repeated twice.
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3.6.5 Effect of Beclin1 Silencing on radiation sensitivity of Hs578t breast
tumor cells
To determine the effect of autophagy inhibition on sensitization of Hs578t
cells to radiation, beclin 1 was silenced and both wild type and beclin-1 silenced
Hs578t cells were irradiated with 5X2 Gy for three days. Then, the number of
viable cells was counted. Figure 3.10 indicates that genetic inhibition of autophagy
does not sensitize Hs578t cells to radiation.
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Figure 3.10 Cell viability assay shows that silencing of Beclin1 failed to sensitize Hs578t cells
to radiation. In each experiment, triplicate samples were used. Two different experiments were
done to confirm the results. (* p value< 0.05 compared IR to control using ANOVA followed by
tukey) (No statistical differences between IR and combination IR+Beclin-/-)
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3.6.6 Effect of the Beclin1 Silencing on the ability to form colonies
Wild type Hs578t breast tumor cells and Hs578t/beclin1- were plated at low
density 150 cells per well, then irradiated for three days with radiation dose 5 X 2
Gy. Plated cells were incubated for 10-14 days. Number of colonies in each well
was counted and calculated as a percentage of control. Figure 3.11 provides
further confirmation that silencing of Beclin 1 does not sensitize Hs578t breast
tumor cells to radiation.
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Clonogenic Survival Assay of Hs578t wild type and Beclin1 silencing breast cells lines
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Figure 3.11 Clonogenic survival assay by silencing Beclin-1 does not sensitize Hs578t
breast tumor cells cells to radiation. In each experiment, triplicate samples were used. Four
different experiments were done to confirm the results. (* p value< 0.05 compared IR to
control using ANOVA followed by tukey)
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3.6.7 Beclin1 was effective in inhibition of autophagy based on Acridine
orange staining
As in the studies using NH4Cl, it was necessary to confirm that the silencing of
beclin was effective in inhibition of autophagy. In Figure 3.12 where studies using
control, beclin-, and combination of beclin- and irradiated cells are presented,
there is minimum induction of autophagic vacuoles in the Beclin-1 silenced cells
while irradiated cells have shown extensive induction of orange color as indicated
by acridine orange staining.
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Figure 3.12 Determination of the inhibition of autophagy after silencing of beclin using Acridine
orange staining. Three different experiments were done to confirm the results and a

representative experiment is shown. All images have the same magnification 20X.
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3.6.8 Degradation of p62 representing autophagic flux

P62 is a protein associated with the nuclear envelope. The complete
process of autophagy is called autophagic flux. To confirm autophagic flux, p62
may be used as a marker. [27] p62 accumulates when autophagy is inhibited, and
decreased levels can be observed when autophagy is induced.

[27]

LC3 is a

receptor for p62. When p62 binds to LC3, autophagy degradation is promoted.
LC3 II is a microtubule-linked protein, which is transformed from LC3I to LC3 II
once autophagy is induced. Therefore, LC3 and p62 are together autophagy
associated proteins and broadly used as markers for autophagy.

Figure 3.13 shows p62 levels in control cells, beclin1-/- cells, irradiated cells and
in irradiation in Hs578t cells where beclin-1 was silenced. While irradiated
parental cells show degradation of p62 that indicates the induction of autophagic
flux, p62 accumulates in the Beclin-1 silenced cells with radiation, indicating that
autophagy has been inhibited.
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Figure 3.13 Western Immunobloting to Assess degradation of p62. All proteins
were collected on Day 5 post radiation. Serum starved cells proteins were
collected after 72 hours of plating.
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3.6.9 Relationship between senescence, autophagy inhibition and irradiation
in Hs578t breast tumor cells using beta galacotosidase staining.

Previous studiess have shown that there is a induction of autophagy and
senescence upon irradiation of Hs578t cells. [45] To assess the relationship
between autophagy, senescence and radiation, cells were plated and treated with
different autophagy inhibitors and then irradiated with 5X2 Gy for three days. On
days 1, 3, 5, and 7 post-radiation, beta galacotosidase staining was performed to
evaluate senescence.

Figure 3.14 confirms, as shown above, that irradiation induces senescence in the
Hs578t cells and that inhibition of autophagy results in a reduction in the extent of
senescence.
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Figure 3.14 Beta Galactosidase staining that shows the reduction of senescence after using
different approaches autophagy inhibitor. Three different experiments were done to confirm
the results. All images have the same magnification 20X.
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2.6.10 Quantification of senescence by flow cytometry for Senescence upon
radiation and silencing of beclin-1
To further evaluate the relationship between senescence and autophagy
inhibition upon radiation, senescence was quantified by FACS analysis in Beclin-1
silenced cells that were irradiated with 5X2 Gy for three days.

In figure 3.15, the irradiated cells show induction of senescence. With the
combination Beclin-/- and irradiation, there is a reduction of the extent of
senescence.
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FACS Analysis of Senescence after Gene Silencing of Autophagy
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Figure 3.15 Quantification of senescence. Hs578t cells were plated and irradiated with
fractionated radiation (5×2Gy) and then were analyzed using Flow cytometry on days 1,3, 5 and 7
post radiation. Silencing of beclin-1 leads to reduction of senescence upon radiation. In each

experiment, triplicate samples were used. Two different experiments were done to
confirm the results. (* p value< 0.05 compared IR to IR+Beclin1 -/- using ANOVA
followed by tukey)
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Section 4: Discussion
4.1 Overview

Radiation is essential as adjuvant therapy in the management TNBC. [48] One
of the major limitations in radiation therapy is the development of resistance. In
theory, sensitization of tumor cells to radiation can be accomplished by inhibition
of cytoprotective autophagy. Inhibition of autophagy can be achieved by using
the anti-malarial drug chloroquine and leads to sensitization of some breast
tumor cell lines to radiation. [36]

Studies from our laboratory have shown that Hs578t cells are relatively
resistant to irradiation compared to other breast cancer cell lines such as MCF7
cells.Also in our laboratory, MCF-7 and ZR-75 breast tumors were sensitized to
radiation upon treatment with an autophagy inhibitors such as chloroquine.

[36][38]

However, inhibition of autophagy by chloroquine fails to sensitize Hs578t breast
cell line to radiation. (Chakradeo S et al under revision). In the current work, we
sought to evaluate the effect of autophagy inhibition using another
pharmacological inhibitor and genetic silencing of autophagy related genes on
the sensitivity of Hs578t cells to radiation.
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4.2 Response of Hs578t cells to radiation

Studies in our laboratory have shown that Hs578t cells are relatively resistant
to irradiation compared to other breast cancer cell lines such as MCF7 cells. [38]
Initial experiments were designed to identify the response of Hs578t breast tumor
cells to radiation. When cells were irradiated with a 5×2 Gy of radiation over a
period of 3 days, cell numbers declined between Day 1 to Day 3 and from Day 3
to Day 7, cells undergo an apparent growth arrest. In our laboratory MDA-MB231 breast tumor cells upon radiation undergo apoptosis and the cells are not
showing recovery. [50] While in Hs578t cells are slightly recovered and showed
sustained growth arresting which indicate the radio resistance of Hs578t
compared to other cell lines. [38]

4.3 Effect of irradiation on autophagy
Autophagy is a catabolic process in which select cellular organelles and
proteins are digested by lysosomal degradation. It has been shown that the
cellular response to radiation in many cell lines is by autophagy.

[40]

Our studies

using Hs578t cells demonstrated that the irradiated cells show l characteristic of
autophagy in that there is an increase in the formation of acidic vacuoles upon
irradiation.
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P62 is a protein complex linked with the nuclear envelope and its degradation
is used as marker of autophagy flux. [27] In this study, the degradation of P62 in
irradiated cells confirms the induction of autophagic flux by irradiation.

4.4 Effect of irradiation on senescence
Several studies have shown that induction of autophagy is associated with the
promotion of senescence in cancer cells. [45] Our observations indicate that
irradiation induces autophagy in Hs578t breast cells line, as furthermore the time
course study of cell viability demonstrated a sustained growth arrest pattern,
which can be an indication of senescence. Our experiments demonstrated that
the irradiated cells show morphological characteristics of cells that undergo
senescence, and there is an increase in the number of cells that stained with Xgal which is a marker for senescence upon irradiation. Our observations suggest
that radiation induces senescence in the Hs578t breast cells line.

4.5 Effect of autophagy inhibition on radiation sensitivity
Autophagy might be responsible for cancer resistance to chemotherapy and
radiation treatment. Inhibition of autophagy can lead to sensitization.[40] In this
study, several experiments were designed to determine whether autophagy
inhibition could sensitize Hs578t breast tumor cells to irradiation.
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Previous data from our laboratory in Hs578t cells using chloroquine and 3-methyl
adenine as pharmacological inhibitors have shown lack of sensitization in
irradiated cells. Use of one more pharmacological inhibitor NH4CL also confirmed
lack of sensitization. To prove that lack of sensitization is not specific to
pharmacological inhibitors, genetic inhibition of radiation-induced autophagy was
assessed, which confirmed lack of sensitization by genetic inhibition. The data of
combination of irradiation and inhibitors of autophagy suggest that Hs578t cells do
not become sensitized to irradiation. However the combination effect might
suggest additive effect rather than sensitization. Since Sensitization is a state of
supra additive outcome where the total effect of two agents is more than the
additive influence of each of those agents separately

4.6 Relationship between autophagy and senescence
Young et al.( 2009) reported that autophagy was an effector mechanism of
senescence and contributed to the establishment of oncogene-induced
senescence. Our laboratory has also generated data that senescence and
autophagy can be dependent on each other. [45] Experiments were designed to
study the relationship between autophagy and senescence induced by radiation
in Hs578t cells. -galactosidase staining was used to assess the relationship
between senescence and autophagy using different pharmacological and genetic
inhibitors of autophagy.

79

Data from beta galactosidase staining suggest that irradiation of Hs578t cells
promote senescence, and that inhibition of autophagy leads to reduction of that
senescence. Flow cytometry quantification of senescent cells confirm the same
results. Thus , a conclusion that can be made that in Hs578t cells, autophagy and
senescence might be closely linked responses.

In conclusion, In MCF-7 breast tumor cells, ionizing radiation stimulated
autophagy that was cytoprotective; pharmacological or genetic inhibition of
autophagy stimulated by radiation resulted in growth suppression and/or cell
killing (mainly by apoptosis). So inhibition of the cytoprotective autophagy can be
used in clinic to sensitize the MCF-7 to radiation. However, in Hs578t breast
tumor cells, ionizing radiation stimulated autophagy that was non-cytoprotective.
So in order to save patients time, using the pharmacological inhibitor of autophagy
is useless in Hs578t treatments. In order to enhance the treatment field of Hs578t
cells, more efforts should be devoted to target the proliferative pathways like
mTor, AKT, MAPK, and PI3K pathways.
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Section5:
Future Experiments

The current findings indicate that the autophagy that is induced by radiation in
the triple negative Hs578t human breast tumor cell line appears to be nonprotective in that inhibition of this autophagy does not increase sensitivity to
radiation. Our findings also show that this autophagy is not cytotoxic, since its
inhibition does not reduce radiation sensitivity.
To further study the role of autophagy in Hs578t cells exposed to radiation,
the influence of autophagy inhibition on radiation sensitivity should be determined
by silencing other autophagy related protein. Since Beclin-1 is one initiator of the
autophagy pathway, silencing another protein that has a role in the late steps of
autophagy, such as ATG7 or ATG5 should be performed.

Previous data from our laboratory has shown that irradiation induces
minimal apoptosis in the Hs578t cells, which does not increase with autophagy
inhibition. The utilization of additional genetic inhibitors of autophagy should
confirm these conclusions. In addition, it would be important to further establish
the relationship between autophagy and senescence, again with the silencing of
additional autophagy related genes. In the long term it would be of value to
identify the signaling elements that distinguish cytoprotective from non-protective
autophagy.
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